🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesPrediabetic and scared - will this actually prevent diabetes? — looking for input Page 2

Prediabetic and scared - will this actually prevent diabetes? — looking for input

CarlaRPh_TPA Fri, Sep 19, 2025 at 1:13 AM 28 replies 1,671 viewsPage 2 of 6
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Sep 19, 2025 at 10:38 PM#6
PharmD_Rodriguez said:
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

My labs after 6 months on glycaemic control: A1C 5.7%, fasting glucose 92 mg/dL, fasting insulin 5 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 7.9% and fasting glucose was 117 mg/dL. The improvement has been dramatic and consistent.

44 14julia.endo, JessicaM_2024, TomFromTexas and 41 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Sep 20, 2025 at 7:09 AM#7
CarlaRPh_TPA said:
Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)124989282
Insulin (fasting)201285
HOMA-IR4.54.02.01.3
Uric Acid8.76.45.95.0

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.

Last edited: Sep 20, 2025 at 12:09 PM
43 13stefan_berlin, Dr.EM_Chicago, pete_RVA and 40 others
Reply Quote Save Share Report
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Sep 20, 2025 at 3:40 PM#8
BenResearch_OR said:
My labs after 6 months on glycaemic control: A1C 5.7%, fasting glucose 92 mg/dL, fasting insulin 5 uIU/mL.

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 29 → 15 → 6 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

Last edited: Sep 20, 2025 at 9:40 PM
42 12Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 39 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Sep 21, 2025 at 12:11 AM#9

Following on from MounjBrad — and this may be the naive question:

What would you measure differently if you were starting again?

41 11Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 38 others
Reply Quote Save Share Report
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Sep 22, 2025 at 5:06 PM#10
Dr.BariatricHTX said:
Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction…

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 38% to 20%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

33 6emily_PDX, Dr.SleepRoch, laura_annarbor and 30 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register